Generalized Anxiety Disorder
📧 Sign up to get email alerts when something new happens for Generalized Anxiety Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD [Phase 3]
Phase 3 trial in generalized anxiety disorder is currently recruiting; no results yet.
-
CLINICAL_TRIALS trial_result · 2024-02-06Clinical Trial Update: Phase 3 Clinical Trial of Buagafuran Capsules in the Treatment of GAD [Phase 3]
Phase 3 trial of buagafuran capsules for generalized anxiety disorder is currently recruiting.
-
FDA approval · 2024-02-05FDA Approved: ESCITALOPRAM — Supplemental Application (Macleods Pharmaceuticals Limited)
FDA approved a supplemental application for escitalopram from Macleods Pharmaceuticals Limited, authorizing changes to the product labeling.
-
FDA approval · 2024-02-05FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Exelan Pharmaceuticals Inc.)
FDA approved a supplemental application for Escitalopram Oxalate (escitalopram) by Exelan Pharmaceuticals Inc. under ANDA078604.
-
FDA approval · 2024-01-30FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Epic Pharma, LLC)
The FDA approved a supplemental application for venlafaxine hydrochloride from Epic Pharma, LLC, supporting the approval of a generic produc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-01-24FDA Approved: PREGABALIN — Supplemental Application (MARKSANS PHARMA LIMITED)
FDA approved a supplemental application for pregabalin submitted by Marksans Pharma Limited (ANDA 216197).
-
FDA approval · 2024-01-19FDA Approved: PAROXETINE — Supplemental Application (ANI Pharmaceuticals, Inc.)
FDA approved a supplemental application for Paroxetine by ANI Pharmaceuticals, Inc., indicating approval of a generic product under ANDA 215…
-
FDA approval · 2024-01-16FDA Approved: DOXEPIN — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for the generic doxepin from Actavis Pharma, Inc., adding regulatory authorization for this prod…
-
FDA approval · 2024-01-03FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for venlafaxine hydrochloride from Aurobindo Pharma Limited, confirming approval of the generic prod…
-
FDA approval · 2023-12-19FDA Approved: DULOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for duloxetine hydrochloride from Aurobindo Pharma Limited, granting regulatory clearance for a gene…
-
FDA approval · 2023-11-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for venlafaxine hydrochloride extended-release (Chartwell RX, LLC), reflecting an approved update to…
-
FDA approval · 2023-11-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Granules Pharmaceuticals Inc.)
The FDA approved a supplemental application for venlafaxine hydrochloride from Granules Pharmaceuticals Inc., authorizing an additional form…
-
FDA approval · 2023-11-01FDA Approved: VENLAFAXINE — Supplemental Application (Zydus Lifesciences Limited)
FDA granted supplemental approval for venlafaxine from Zydus Lifesciences Limited, signaling an approved modification to an existing generic…
-
CLINICAL_TRIALS trial_result · 2023-10-26Clinical Trial Update: A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity [Phase 4]
A Phase 4 randomized, placebo-controlled crossover trial evaluated methylphenidate hydrochloride controlled release capsules in adults with …
-
FDA approval · 2023-10-18FDA Approved: ALPRAZOLAM — Supplemental Application (Natco Pharma USA LLC)
FDA approved a supplemental application for Alprazolam from Natco Pharma USA LLC under an ANDA, updating the regulatory status of the produc…
-
FDA approval · 2023-09-27FDA Approved: LORAZEPAM — Supplemental Application (Aurolife Pharma LLC)
The FDA approved a supplemental application for lorazepam from Aurolife Pharma LLC, enabling the commercialization of a generic Lorazepam pr…
-
FDA approval · 2023-08-21FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Venlafaxine from BluePoint Laboratories, confirming a generic venlafaxine product (venlafaxine h…
-
FDA approval · 2023-08-21FDA Approved: VENLAFAXINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves a supplemental application for Venlafaxine from Sun Pharmaceutical Industries, Inc., updating the generic product under ANDA 07…
-
FDA approval · 2023-08-18FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for venlafaxine hydrochloride, a generic antidepressant.
-
FDA approval · 2023-08-18FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Vertical Pharmaceuticals, LLC)
FDA approved a supplemental application for venlafaxine hydrochloride by Vertical Pharmaceuticals, LLC.
-
FDA label_change · 2023-08-18FDA Approved: VENLAFAXINE — Supplemental Application (Alembic Pharmaceuticals Inc.)
The FDA approved a supplemental application for venlafaxine from Alembic Pharmaceuticals, resulting in labeling updates for the generic prod…
-
FDA approval · 2023-08-18FDA Approved: ESCITALOPRAM OXALATE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for escitalopram oxalate from Rising Pharma Holdings, Inc., marking a supplemental approval for …
-
FDA approval · 2023-08-18FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Yaopharma Co., Ltd.)
FDA approved a supplemental application for venlafaxine hydrochloride from Yaopharma Co., Ltd., enabling the generic drug to be marketed. Th…
-
FDA approval · 2023-08-18FDA Approved: DRIZALMA SPRINKLE — Supplemental Application (SUN PHARMACEUTICAL INDUSTRIES, INC.)
The FDA approved Sun Pharmaceutical's supplemental NDA for Drizalma Sprinkle (duloxetine), adding a sprinkle-form formulation and related la…
-
FDA approval · 2023-08-18FDA Approved: EFFEXOR XR — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Effexor XR (venlafaxine hydrochloride) from Viatris Specialty LLC. The approval updates the …